Targets › METTL3
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Nov 2027.
The METTL3-METTL14 heterodimer forms a N6-methyltransferase complex that methylates adenosine residues at the N(6) position of some RNAs and regulates various processes such as the circadian clock, differentiation of embryonic and hematopoietic stem cells, cortical neurogenesis, response to DNA damage, differentiation of T-cells and primary miRNA processing. In the heterodimer formed with METTL14, METTL3 constitutes…. (UniProt, Q86U44)
Open in Phaseline: the race on METTL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Epics Therapeutics | EP102 METTL3 modulator | METTL3 | Phase 1 | Advanced Solid Tumor (Phase 1) | Nov 2027 |
| STORM Therapeutics | STC-15 METTL3 inhibitor | METTL3 | Phase 1 | Solid Tumor | Dec 2027 |
Advanced Solid Tumor (Phase 1) (1) Solid Tumor (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.